148 related articles for article (PubMed ID: 7692455)
41. PGE(1) short term therapy in critical lower limb ischemia.
Bandiera G; Forletta M; Di Paola FM; Cirielli C
Int Angiol; 2003 Mar; 22(1):58-63. PubMed ID: 12771858
[TBL] [Abstract][Full Text] [Related]
42. Short-term and long-term effects of one-week treatment with intravenous iloprost in critical limb ischemia patients (Leriche-Fontaine stage III and IV).
Meini S; De Franco V; Auteri A; Setacci C; Di Renzo M; Pieragalli D
Int Angiol; 2005 Mar; 24(1):64-9. PubMed ID: 15877001
[TBL] [Abstract][Full Text] [Related]
43. [Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative].
Brock FE; Abri O; Baitsch G; Bechara G; Beck K; Corovic D; Diehm C; Marshall M; Rahmel B; Scheffler P
Schweiz Med Wochenschr; 1990 Oct; 120(40):1477-82. PubMed ID: 1699272
[TBL] [Abstract][Full Text] [Related]
44. Does prostacyclin analogue Iloprost change blood rheology? Results from a double blind trial with intravenous application in diabetics.
Ernst E; Marshall M; Matrai A
Vasa; 1988; 17(2):89-91. PubMed ID: 2457284
[No Abstract] [Full Text] [Related]
45. [Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
Heidrich H
Vasa Suppl; 1991; 33():346-7. PubMed ID: 1788752
[TBL] [Abstract][Full Text] [Related]
46. [Placebo controlled, double-blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease].
Stiegler H; Diehm C; Grom E; Martin M; Mörl H; Rudofsky G; Vogelberg KH
Vasa Suppl; 1992; 35():164-6. PubMed ID: 1481031
[No Abstract] [Full Text] [Related]
47. Skin oxygen pressure histograms in patients with peripheral arterial occlusive disease during intraarterial and intravenous prostaglandin E1 infusions of different dosages and their prognostic value.
Creutzig A; Arnold A; Caspary L; Thum J; Alexander K
Angiology; 1995 May; 46(5):357-67. PubMed ID: 7741319
[TBL] [Abstract][Full Text] [Related]
48. The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia.
Mazzone A; Cusa C; Bucci L; Vezzoli M; Ghio S; Buggia I; Regazzi MB; Fossati G; Mazzucchelli I; Gritti D
Eur J Clin Invest; 1999 Jan; 29(1):1-5. PubMed ID: 10092981
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic efficacy of intravenously applied prostaglandin E1.
Scheffler P; de la Hamette D; Leipnitz G
Vasa Suppl; 1989; 28():19-25. PubMed ID: 2609240
[TBL] [Abstract][Full Text] [Related]
50. [Reflex oximetry for evaluating blood redistribution in patients with arterial occlusive disease treated with PGE1].
Thum J; Caspary L; Creutzig A; Alexander K
Vasa Suppl; 1992; 35():39-41. PubMed ID: 1481056
[No Abstract] [Full Text] [Related]
51. Cocaine-related peripheral vascular occlusive disease treated with iloprost in addition to anticoagulants and antibiotics.
Mazzone A; Giani L; Faggioli P; Pichini S; Pacifici R
Clin Toxicol (Phila); 2007; 45(1):65-6. PubMed ID: 17357385
[TBL] [Abstract][Full Text] [Related]
52. Short- and long-term treatments with iloprost in diabetic patients with peripheral vascular disease: effects on the cardiovascular risk factor plasminogen activator inhibitor type-1.
Cozzolino D; Coppola L; Masi S; Salvatore T; Sasso FC; De Lucia D; Gentile S; Torella R
Eur J Clin Pharmacol; 1999 Sep; 55(7):491-7. PubMed ID: 10501817
[TBL] [Abstract][Full Text] [Related]
53. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.
Grant SM; Goa KL
Drugs; 1992 Jun; 43(6):889-924. PubMed ID: 1379160
[TBL] [Abstract][Full Text] [Related]
54. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.
Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D
BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734
[TBL] [Abstract][Full Text] [Related]
55. Spontaneous laser doppler flux distribution in ischemic ulcers and the effect of prostanoids: a crossover study comparing the acute action of prostaglandin E1 and iloprost vs saline.
Gschwandtner ME; Koppensteiner R; Maca T; Minar E; Schneider B; Schnürer G; Ehringer H
Microvasc Res; 1996 Jan; 51(1):29-38. PubMed ID: 8812752
[TBL] [Abstract][Full Text] [Related]
56. [Treatment of chronic atherosclerotic obliterative arteriopathy in the II and IV Fontaine stage. Personal observations using iloprost].
Marci M; Raffa S; Panzini E; Russo F
Clin Ter; 1994 Dec; 145(12):469-74. PubMed ID: 7536648
[TBL] [Abstract][Full Text] [Related]
57. Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease.
Thum J; Caspary L; Creutzig A; Alexander K
Vasa; 1998 May; 27(2):100-5. PubMed ID: 9612114
[TBL] [Abstract][Full Text] [Related]
58. [Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].
Weiss T
Vasa; 2003 Nov; 32(4):187-92. PubMed ID: 14694766
[TBL] [Abstract][Full Text] [Related]
59. Iloprost and peripheral arterial disease in diabetic patients.
Vicari AM; Chiesa R; Mari G; Galimberti M; Di Carlo V; Pozza G
Acta Diabetol Lat; 1991; 28(1):113-4. PubMed ID: 1713729
[No Abstract] [Full Text] [Related]
60. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study.
Darius H; Hossmann V; Schrör K
Klin Wochenschr; 1986 Jun; 64(12):545-51. PubMed ID: 2426514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
